A 2023 analysis published in the Journal of Obesity Research found that patients receiving lipotropic injections alongside GLP-1 therapy lost 3.2% more body weight over 16 weeks compared to GLP-1 monotherapy
patients receiving ADMs saw noticeable spikes in the rate of discontinuation due to medication availability in January 2023 (5.3%) and June 2024 (4.8%), while patients receiving AOMs experienced higher rates of discontinuation due to medication availability throughout 2023 and into early 2024
These injections are perfect for men who train hard, recover often and want to optimize both body composition and performance
S., Esbjerg, S., & Ryan, D
Like me, theyve turned to research-grade peptides labeled not for human consumption, shipped from overseas suppliers with no prescriptions, no oversight, and no guarantees